PolypDx™ for Clinicians.
PolypDx™ was developed and validated in a large-scale (nearly 1000-patient) clinical trial in Alberta, Canada in conjunction with University of Alberta, the Edmonton Colon Cancer Screening Program (Scope), and Alberta Health Services (formerly, Capital Health).
At a high specificity of 48%, PolypDx™ detects 79% of the colonic adenomatous polyps, a significantly higher sensitivity than other fecal-based tests for the detection of adenomatous polyps.
PolypDx™ is currently available as a laboratory-developed test through a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory in the U.S.
View Clinicial Studies:
The science behind the test.
PolypDx™ is a metabolomics-based screening test designed for high-throughput screening, using Liquid Chromatography–Mass Spectrometry (LC-MS) technology.
PolypDx™ is based on the analysis of key metabolomic biomarkers in urine. The biomarker measurement data are interpreted by a proprietary algorithm which generates the PolypDx™ test result.
COLLECT URINE SAMPLE AND SHIP TO TESTING FACILITY.
SAMPLES ARE PREPARED FOR Liquid Chromatography-Mass Spectrum Technology TESTING.
TESTING ANALYZES METABOLOMIC BIOMARKERS.
RESULTS ARE RETURNED TO PRESCRIBING DOCTOR.
RESULTS CONFIRMED AND RELAYED TO PATIENT.
Interpreting the results.
A positive result would indicate the patient is likely to have a polyp and further investigation, such as a follow up with a colonoscopy, is strongly recommended.
A negative result would indicate the patient is less likely to have a polyp. Patients may still require further investigation, regular interval surveillance for polyp detection is recommended.